Remdesivir: a review in COVID-19
HA Blair - Drugs, 2023 - Springer
Remdesivir (Veklury®), a nucleotide analogue prodrug with broad-spectrum antiviral activity,
is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by …
is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by …
[HTML][HTML] Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital …
M Lucijanić, N Bušić, P Bistrović, I Papić… - Croatian medical …, 2022 - ncbi.nlm.nih.gov
Aim To evaluate the association of remdesivir use and the survival of hospitalized patients
with coronavirus disease 2019 (COVID-19). Methods We retrospectively reviewed the …
with coronavirus disease 2019 (COVID-19). Methods We retrospectively reviewed the …
Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort
M Karolyi, A Gruebl, S Omid, M Saak, E Pawelka… - Infection, 2023 - Springer
Background Tocilizumab and baricitinib are recommended treatment options for
hospitalized COVID-19 patients requiring oxygen support. Literature about its efficacy and …
hospitalized COVID-19 patients requiring oxygen support. Literature about its efficacy and …
Temporal trends in 90-day survival of hospitalised individuals during two years of the COVID-19 pandemic in Denmark
C Leding, CL Clausen, MS Roldgaard… - Infectious …, 2024 - Taylor & Francis
Background Mortality rates peaked early in the COVID-19 pandemic and then declined.
Possible explanations are pharmacological and non-pharmacological treatments, vaccines …
Possible explanations are pharmacological and non-pharmacological treatments, vaccines …
Prognostic factors for poor outcomes in patients with severe COVID-19 treated with remdesivir plus dexamethasone in Taiwan
YH Lai, YC Lee, IR Chen, SN Lin, YL Chang… - Journal of Microbiology …, 2023 - Elsevier
Abstract Background Coronavirus disease-2019 (COVID-19) remains a global public health
concern, and remdesivir plus dexamethasone combination therapy is suggested for patients …
concern, and remdesivir plus dexamethasone combination therapy is suggested for patients …
[HTML][HTML] COVID-19 treatment strategies with drugs centrally procured by the German Federal Ministry of Health in a representative tertiary care hospital: a temporal …
K Marx, S Kalbitz, N Kellner, M Fedders… - GMS Infectious …, 2023 - ncbi.nlm.nih.gov
Methods: A descriptive analysis of hospitalization and treatment of COVID-19 patients with
drugs centrally procured by the BMG at St. Georg Hospital, Leipzig, Germany, for the period …
drugs centrally procured by the BMG at St. Georg Hospital, Leipzig, Germany, for the period …
ABO blood group and effectiveness of tocilizumab in clinical response to COVID-19: A single center, retrospective study.
IAR Nasution, R Andrajati… - Pharmaceutical …, 2023 - search.ebscohost.com
As an anticytokine therapy, tocilizumab has been recommended for the management
therapy in patients with severe and serious COVID-19 cases. The association between the …
therapy in patients with severe and serious COVID-19 cases. The association between the …
[PDF][PDF] Effectiveness and Safety of Combination Drug Therapy in Covid-19 patients admitted in a Designated Covid Hospital
S Kizhedath, S Venugopal, SKK Balakumaran… - 2023 - researchgate.net
Background: The corona virus disease (COVID-19) caused by the severe acute respiratory
syndrome coronavirus 2 (SARS CoV-2) virus has affected the whole world. Researches are …
syndrome coronavirus 2 (SARS CoV-2) virus has affected the whole world. Researches are …
Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study
M Miyazaki, R Yanagida, A Nakashima, K Matsuo… - Medicina, 2022 - mdpi.com
Background and Objectives: Remdesivir (RDV) is the first antiviral agent approved in Japan
for the treatment of coronavirus disease 2019 (COVID-19). The aim of our study was to …
for the treatment of coronavirus disease 2019 (COVID-19). The aim of our study was to …
Clinical outcome of Remdesivir in the treatment of a severe and critically ill elderly patient with COVID-19 infection.
S Mohamed Saleh… - … Egyptian Journal of …, 2023 - ejgg.journals.ekb.eg
Background: Antiviral effect of remdesivir against SARS-CoV-2 is still controversial, during
the COVID-19 pandemic, using antiviral drugs may be an efficient strategy as there is no …
the COVID-19 pandemic, using antiviral drugs may be an efficient strategy as there is no …